Dr. Soon-Shiong became the largest individual shareholder in Celgene after the company acquired his pharma company Abraxis for $4.5 billion in 2010, the report states.The billionaire physician invented the cancer drug Abraxane, which became one of Celgene’s blockbuster drugs after studies said the drug was able to extend the lives of patients with pancreatic cancer.
As part of the proposed deal, Bristol-Myers Squibb will give shareholders one if its own shares plus $50 for each of Celgene’s shares. The stock price for Celgene’s shares jumped 31 percent after news of the merger broke Jan. 3.
News of the deal pushed Dr. Soon-Shiong’s net worth up at least $194 million to an estimated $6.9 billion, according to Forbes‘ real-time rankings of the world’s billionaires.
To access the full report, click here.
More articles on pharmacy:
House panel launches drug-pricing probe of 12 pharma companies
Key thoughts on controlling pharmacy spend for hospitals
Dispensary of Hope’s pharmaceutical director Dr. Hillary Blackburn on what makes a dynamic, influential leader
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
